---
title: "Grand Pharmaceutical Wins China’s First Approval for Demodex Blepharitis Drug, Bolstering Ophthalmic Push"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280049477.md"
description: "Grand Pharmaceutical Wins China’s First Approval for Demodex Blepharitis Drug, Bolstering Ophthalmic Push"
datetime: "2026-03-22T10:07:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280049477.md)
  - [en](https://longbridge.com/en/news/280049477.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280049477.md)
generator: "portal-rs"
---

# Grand Pharmaceutical Wins China’s First Approval for Demodex Blepharitis Drug, Bolstering Ophthalmic Push

Grand Pharmaceutical Wins China’s First Approval for Demodex Blepharitis Drug, Bolstering Ophthalmic Push

### Related Stocks

- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [000963.CN](https://longbridge.com/en/quote/000963.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [SXTC.US](https://longbridge.com/en/quote/SXTC.US.md)

## Related News & Research

- [China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering | SXTC Stock News](https://longbridge.com/en/news/293620364.md)
- [China SXT Pharmaceuticals Secures Up to $30 Million in New Pre‑Paid Share Financing](https://longbridge.com/en/news/291844635.md)
- [CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 million](https://longbridge.com/en/news/296243257.md)
- [China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New High](https://longbridge.com/en/news/293168428.md)
- [Asymchem Q1 2026 Revenue Rises but Profit Edges Lower](https://longbridge.com/en/news/284223624.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**